TP53 and cancer: In the dataset of CNA that we analyzed in this study the 62% of the patients having a homozygous deletion of TP53 also have FXR2 homozygously deleted.It has been demonstrated that in human cancer it is possible to selectively block cell proliferation by inhibiting, in those cells deleting FXR2, the remaining family member FXR1 [27].